doc1021
Vaccineexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 17, 2025 (NCT06805305)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288112 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2026 | Diakonos Oncology Corporation |
| NCT06805305 | Phase 2 | Mar 17, 2025 | Diakonos Oncology Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Diakonos Oncology Corporation | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1